Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 34 of 34

Filter Applied: cost effectiveness (Click to remove)

HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998

HIV-1 Protease Inhibitors
JAMA 227:145-149, Deeks,S.J.,et al, 1997

HIV Infection-1
BMJ 314:487-491, 579-5831997., Cohn,J.A., 1997

Role of Brain Biopsy in the Management of Focal Brain Lesions in HIV-Infected Patients
Neurol 54:993-997, Antinori,A.,et al, 2000

Evaluation and Management of Intracranial Mass Lesions in AIDS
Rpt of Quality Stnds Subcomm of the AAN, Neurol 50:21-261998., , 1998

The Impact of Neurologic Disease on Hospitalizations Related to HIV Infection in Maryland, 1991-1992
Arch Neurol 54:846-852, DalPan,G.J.,et al, 1997

Management Protocol for an Enhancing Cerebral Lesion in HIV Infection
Conn Medicine 60:649-651, Finelli,P.F., 1996

Electroencephalography
JNNP 57:1308-1319, Binnie,C.D.&Prior,P.F., 1994

Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021

Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared with Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
Stroke 49:1464-1470, Reddy, V.Y.,et al, 2018

Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017

Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013

Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012

Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011

Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011

Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
JAMA 293:699-706, OBrien,C.L. &Gage,B.F., 2005

The New Antiepileptic Drugs, Clinical Applications
JAMA 291:615-620, LaRoche,S.M.&Helmers,S.L., 2004

Stalevo for Parkinson's Disease
The Medical Letter 46:39, , 2004

Long-term Donepezil Treatment in 565 Patients with Alzheimer's Disease (AD2000): Randomised Double-Blind Trial
Lancet 363:2105-2115,2100, AD2000 Collaborative Group, 2004

Economic Evaluation of Donepezil in Moderate to Severe Alzheimer Disease
Neurol 63:644-650, Feldman,H.,et al, 2004

Blood Pressure Control in Stroke Patients
Neurol 59:23-25, Messerli,F.H.,et al, 2002

Drugs for Alzheimer's Disease
BMJ 323:123-124, O'Brien,J.T . &Ballard,C.G., 2001

Comtan (Entacapone) The Treatment of Parkinson's Disease, Questions & Answers
APDA Ed Suppl #15, Watts,R.L., 2001

Rivastigmine (Exelon) for Alzheimer's Disease
The Medical Letter 42:93-94, , 2000

Cost-Effectiveness of Donepezil in the Treatment of Mild or Moderate Alzheimer's Disease
Neurol 52:1138-1145,1115, Neumann,P,J.,et al, 1999

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999

Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999

Glatiramer Acetate for Relapsing Multiple Sclerosis
The Medical Letter 39:61-62, , 1997

Donepezil (Aricept) for Alzheimer's Disease
The Medical Letter 39:53-54, , 1997

The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997

Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996

The Impact of New Pharmaceutical Agents on the Cost of Neurologic Care
Neurol 45:569-572, Gunderson,C.H., 1995

Brain Single-Photon Emission Computed Tomography
Neurol 44:1970-1977, Masdeu,J.C.,et al, 1994



Showing articles 0 to 34 of 34